Rein Therapeutics Inc (RNTX) Stock Forecast
RNTX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 2 analysts
- Price target
- $6.00 average of analyst targets
- Upside to target
- +916.9% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.10
- 52-week range
- $0.59 – $1.88
RNTX analyst ratings
2 analystsNumber of analysts at each rating.
RNTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RNTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.10 | −$0.10 | −$0.10 | −$0.21 | +52.4% | 2 |
| Current fiscal year (2026) | −$0.46 | −$0.47 | −$0.45 | −$1.96 | +76.5% | 2 |
| Next fiscal year (2027) | −$0.47 | −$0.50 | −$0.43 | −$0.46 | −1.1% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RNTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 2 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 2 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 2 |
RNTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RNTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.35 | −$0.10 | −$0.10 | −$0.09 | −$0.10 | −71.4% | 1 up · 0 down |
| Current fiscal year (2026) | −$1.63 | −$0.53 | −$0.53 | −$0.44 | −$0.46 | −71.8% | 1 up · 0 down |
| Next fiscal year (2027) | −$1.33 | −$0.50 | −$0.50 | −$0.41 | −$0.47 | −65.0% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
RNTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; RNTX beat in 6 of 12.
What analysts expect from RNTX
2 analysts cover Rein Therapeutics; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $6.00, 916.9% above the latest close of $0.59. Analysts expect earnings of −$0.46 per share for 2026, +76.5% from a year earlier. For 2027 the average estimate is −$0.47 per share. Rein Therapeutics beat the EPS estimate in 6 of the last 12 quarters.
Related: RNTX income statement, RNTX key metrics, RNTX chart. See the RNTX stock overview for the latest quote and news.
RNTX forecast FAQ
What is Rein Therapeutics's price target?
The average analyst price target for Rein Therapeutics is $6.00, 916.9% above the latest close of $0.59.
Is Rein Therapeutics a buy, hold or sell?
Of 2 analysts covering Rein Therapeutics, 1 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Rein Therapeutics's EPS forecast?
Analysts forecast −$0.46 per share for 2026 (range −$0.47 to −$0.45); for 2027 the estimate is −$0.47.
When does Rein Therapeutics report earnings?
Rein Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-0.10.
Does Rein Therapeutics usually beat earnings estimates?
Rein Therapeutics reported EPS at or above the analyst estimate in 6 of the last 12 quarters.